Scientists say they now know what went wrong with Johnson & Johnson’s Covid vaccine
The U.S. Food and Drug Administration authorized Johnson & Johnson’s Covid vaccine for emergency use in February 2021,…
Is Johnson & Johnson a Buy, Sell, or Hold in 2026?
While artificial intelligence (AI) stocks are dominating debates and headlines on Wall Street, companies in other sectors can…
Johnson & Johnson (JNJ) Q4 earnings
Johnson & Johnson said on Thursday that it has reached an agreement with the U.S. President administration to…
The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth
jetcityimage / iStock Editorial via Getty Images Lilly posted 53.9% revenue growth and 480% net income growth driven…
Johnson & Johnson, U.S. agree on drug discounts, new plants
Key Terms
tariffs
regulatory
Tariffs are taxes imposed by a government on goods…
Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever
Bristol Myers Squibb is a pharmaceutical giant with a solid dividend history. Medtronic is a high-yield medical device…
5 Dividend Powerhouses That Belong in Every Retirement Portfolio Right Now
24/7 Wall St Verizon offers the highest yield at 6.59% with a 0.32 beta and 19 consecutive years…
Johnson & Johnson (JNJ) Announces Updated Results From the Phase 3 CARTITUDE-4 Study
Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in. Johnson & Johnson (NYSE:JNJ) announced…
1 Major Factor Behind the Healthcare Sector’s Recent Surge
Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other…
Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers
AI chip maker Nvidia’s fresh partnerships with Eli Lilly and Johnson & Johnson point to a broader trend…
Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers
AI chip maker Nvidia’s fresh partnerships with Eli Lilly and Johnson & Johnson point to a broader trend…
Texas AG Ken Paxton moves to block Tylenol maker dividend amid lawsuit over marketing
Texas Attorney General Ken Paxton has filed a motion to block Kenvue, the maker of Tylenol, from issuing…